ASX vs. TER: Which AI Semiconductor Stock Should You Buy Right Now?

Teradyne reported record Q2 2026 revenue of $1.33 billion, up more than 100% year over year, with AI-related sales exceeding 60% of revenue; Semi Test revenue rose 128% to more than $1 billion and compute revenue grew nearly 600%. The article favors TER as a buy over ASE Technology, citing stronger AI-driven testing, memory, product-test and robotics demand, although TER trades at a higher 30.99x forward P/E versus ASX's 21.04x. ASE's advanced-packaging growth remains robust—ATM revenue rose 36% and gross margin expanded 540bps to 27.3%—but extensive capacity buildouts and weaker EMS margins present execution and profitability risks.

Analysis

TER is transitioning from a cyclical SoC-test supplier into a broader AI-infrastructure verification play spanning compute, HBM, optics and high-speed interconnects. That diversification matters: sustained demand across these vectors can support a higher through-cycle earnings floor and justify some premium multiple, while correlation wins at additional hyperscalers create a multi-quarter share-gain catalyst rather than merely a unit-volume recovery. The near-term risk is that the current multiple leaves little tolerance for a normalization in AI tester utilization or delayed GPU platform ramps; any sequential book-to-bill deceleration would likely compress the stock faster than estimates fall.

ASX offers the more asymmetric 6-18 month setup if advanced-packaging capacity comes online on schedule. Its incremental LEAP mix should raise consolidated profitability disproportionately, but the market will likely discount the benefit until utilization of new tools is visible; heavy investment also creates a free-cash-flow trough and raises the cost of even modest schedule slippage. The overlooked read-through is for packaging-equipment suppliers such as AMAT and LRCX: ASE's expansion supports tool demand, although OSAT capacity additions globally could ultimately constrain pricing if AI demand broadens less rapidly than anticipated.

Consensus is treating TER's AI exposure as inherently higher quality than ASX's capacity-constrained packaging exposure. That is directionally reasonable for the next one to three quarters, but tester demand is typically more volatile because customers can defer capital purchases, whereas qualified advanced packaging capacity is difficult to substitute once designed into a high-end accelerator. The key falsifier for the ASX rerating is failure to deliver a sustained ATM-margin expansion despite rising LEAP revenue; for TER, it is compute or memory orders reverting toward replacement-cycle levels rather than extending into 2027.

Key Decisions for Investors

• Maintain a 1-3 month long TER / short ASX pair only after TER confirms continued order momentum at the next earnings update; target 10-15% relative outperformance, with a 7% relative stop if TER book-to-bill or forward revenue guide softens.
• Build ASX on 6-18 month weakness rather than chase TER: initiate a starter position if execution concerns drive a 10-15% pullback, and add only after evidence of on-time capacity installation and durable ATM gross margin above 30%. The rerating case is margin mix and capacity monetization, not EMS recovery.
• For TER holders, protect post-run gains with 3-6 month put spreads around the next results date; the principal downside is multiple compression from a single-cycle order pause, even if the longer-term AI thesis remains intact.
• Watch AMAT and LRCX for incremental advanced-packaging tool orders and ASX capex procurement disclosures. Treat this as an alert rather than a position until order attribution and timing are independently confirmed.
• Avoid QBTS as a read-through trade: the semiconductor-test and packaging cycle does not create a direct earnings mechanism for quantum-computing vendors.